T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives

Abstract EN

Type 1 diabetes (T1D) is an autoimmune disease driven by the activation of lymphocytes against pancreatic β-cells.

Among β-cell autoantigens, preproinsulin has been ascribed a key role in the T1D process.

The successive steps that control the activation of autoreactive lymphocytes have been extensively studied in animal models of T1D, but remains ill defined in man.

In man, T lymphocytes, especially CD8+ T cells, are predominant within insulitis.

Developing T-cell assays in diabetes autoimmunity is, thus, a major challenge.

It is expected to help defining autoantigens and epitopes that drive the disease process, to pinpoint key functional features of epitope-specific T lymphocytes along the natural history of diabetes and to pave the way towards therapeutic strategies to induce immune tolerance to β-cells.

New T-cell technologies will allow defining autoreactive T-cell differentiation programs and characterizing autoimmune responses in comparison with physiologically appropriate immune responses.

This may prove instrumental in the discovery of immune correlates of efficacy in clinical trials.